Stockings of Cambridge The participant is shown two displays containing three colored balls. There is a row of numbered boxes along the bottom of the screen. The test administrator first demonstrates to the participant how to use the balls in the lower display to copy the pattern in the upper display, and completes Inhibitors,research,lifescience,medical one demonstration problem, where the solution requires one move. The participant must then complete three further problems, one each of two moves, three moves, and four moves. Next the participant is shown further problems and

must work out in their head how many moves the solutions to these problems require, then touch the appropriate box at the bottom of the screen to Inhibitors,research,lifescience,medical indicate their response. Stockings of Cambridge primarily measures executive function. Outcome measures were problems solved on first choice (the number of problems which were solved on the subject’s first choice), with a higher score being better; mean selleck kinase inhibitor choices to correct (the

mean number of unique box choices that the subject made on each problem to make the correct choice), with a lower score being better; Inhibitors,research,lifescience,medical latency to first choice (measured from the appearance of the balls on the screen until the box was touched), with a lower score being better; and latency to correct (measured from the appearance of the balls on the screen until the correct box was touched), with a lower score being better. Inhibitors,research,lifescience,medical Clinical measures The clinical symptom ratings included the PANSS consisting of 7 items for positive symptoms, 7 items for negative symptoms and 16 items for evaluation of general psychopathology, used in combination with and the ‘The Structured Clinical Interview PANSS’ (SCI-PANSS) [Kay et al. 1987, 1991]. Statistical analysis All analyses were

performed as completers analyses and intention-to-treat analyses, using the last observation carried forward (LOCF) principle. Participants were classified according to study drug, for example, sertindole versus Inhibitors,research,lifescience,medical olanzapine. All participants receiving at least one drug dose and selleck products completing at least one cognitive test were included in the intention-to-treat analysis (LOCF). Due to a very low inclusion number in the study, only descriptive analyses with mean scores were conducted. The Mann–Whitney Cilengitide U test was employed. To reduce the risk of type II errors, a correction was applied to the standard p < 0.05 significance criterion. The Bonferroni correction was judged to be too conservative in an explorative study with respect to the risk of type I errors. We selected p < 0.01 as a reasonable significance criterion. The study was approved by the Danish Medicines Agency, Data Protection Agency and the Regional Committee on Biomedical Research Ethics of North Jutland.